Approved |
|
|
|
|
|
|
|
Neupogen/Neulasta
more info |
 |
A+/A3 |
Cancer, white blood cell stimulant |
#1 |
Sole |
$5,352 |
MSK |
| |
|
|
|
|
|
|
|
Remicade
more info |
   |
AAA/Aaa
AA-/Aa3 |
Rheumatoid Arthritis (RA), UC, Crohn´s, PsA, AS, Psoriasis |
#1
#3 |
#2 / #1
#1 |
$7,627 |
NYU |
| |
|
|
|
|
|
|
|
Humira
more info |
 |
AA/A1 |
Rheumatoid Arthritis (RA), UC,
Crohn´s, PsA, AS, Psoriasis |
#1 |
#1 / #2 |
$9,266 |
AstraZeneca |
| |
|
|
|
|
|
|
|
Rituxan - US
more info |
   |
AA-/A2 |
B-cell Lymphoma, RA,
Multiple Sclerosis, Lupus |
#1 |
#1 |
$3,300 |
XOMA |
| |
|
|
|
|
|
|
|
Atripla/Truvada/
Emtriva/Complera (3)
more info |
  |
NR
A+/A2
AA-/Aa3 |
HIV/AIDS |
#1 |
#1 |
$7,128 (3) |
Emory |
| |
|
|
|
|
|
|
|
Thalomid
more info |
 |
NR/NR |
Multiple Myeloma |
#4 |
#2 |
$294 |
Entre Med |
| |
|
|
|
|
|
|
|
Lyrica
more info |
 |
AA/A1 |
Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, Onset Seizures and Fibromyalgia |
#1 |
#1 |
$4,158 |
Northwestern University |
| |
|
|
|
|
|
|
|
Prezista
more info |
|
AAA/Aaa |
HIV/AIDS |
- - |
- - |
$1,414 |
PharmaCo |
| |
|
|
|
|
|
|
|
Letairis/Volibris
more info |
 |
NR |
PAH |
- - |
#2 |
$612 |
PharmaCo |
| |
|
|
|
|
|
|
|
RotaTeq
more info |
 |
AA-/Aa3 |
Rotavirus Vaccine |
- - |
#1 |
$614 |
CHOP |
| |
|
|
|
|
|
|
|
Cubicin
more info |
   |
NR
NR
AA-/AA2 |
cSSSI, Bacteremia, Endocarditis |
- - |
#2 |
$864 |
Not Disclosed |
| |
|
|
|
|
|
|
|
Savella
more info |
 |
NR |
Fibromyalgia |
- - |
#3 |
$103 |
Cypress Bioscience |
| |
|
|
|
|
|
|
|
Myozyme/Lumizyme
more info |
 |
A-/BBB+ |
Pompe Disease |
#2 |
#1 |
$597 |
Academic Institution |
| |
|
|
|
|
|
|
|
Lexiscan
more info |
 |
NR |
Pharmacological Stress Agent for MPI |
#2 |
#1 |
$567 |
Not Disclosed |
| |
|
|
|
|
|
|
|
Januvia/Janumet
more info |
|
AA-/Aa3 |
Diabetes |
#1 |
#1 |
$5,746 |
Astellas |
| |
|
|
|
|
|
|
|
Onglyza/Kombiglyze
more info |
 |
A+/A2 |
Diabetes |
-- |
#3 |
$547 |
Astellas |
| |
|
|
|
|
|
|
|
Galvus/Eucreas
more info |
|
NR |
Diabetes |
-- |
#2 |
$910 |
Astellas |
| |
|
|
|
|
|
|
|
Nesina
more info |
 |
NR |
Diabetes |
-- |
#4 |
$257 |
Astellas |
| |
|
|
|
|
|
|
|
Tradjenta
more info |
  |
-- |
Diabetes |
-- |
#5 |
$89 |
Astellas |
| |
|
|
|
|
|
|
|
TOBI
more info |
|
AA-/- |
Anti-Infectives (cystic fibrosis) |
-- |
-- |
317 |
Inventor |
| |
|
|
|
|
|
|
|
Viviant
more info |
|
AA/A1 |
2nd gen. SERM: Osteoporosis |
Best in Class |
-- |
-- |
Ligand |
| |
|
|
|
|
|
|
|
Cimzia
more info |
 |
NR |
Rheumatoid Arthritis (RA), Crohn's |
#2 |
#3 |
$595 |
Nektar Therapeutics |
| |
|
|
|
|
|
|
|
Mircera
more info |
|
AA-/A2 |
Chronic Kidney Disease (CKD) |
-- |
#2 |
$416 |
Nektar Therapeutics |
| |
|
|
|
|
|
|
|
Tecfidera
more info |
|
A- |
Psoriasis, Multiple Sclerosis |
- - |
- - |
-- |
Fumapharm AG Shareholders |
| |
|
|
|
|
|
|
|
In Development |
|
|
|
|
|
|
|
Vosaroxin
more info |
 |
|
Acute Myeloid Leukemia (AML) |
|
|
-- |
Sunesis |
| |
|
|
|
|
|
|
|
Conbriza/Aprela (4)
more info |
|
AA/A1 |
2nd gen. SERM: Osteoporosis |
Best in Class |
- - |
-- |
Ligand |
| |
|
|
|
|
|
|
|
| |
 |
|
|
|
|
|
|
| |
|
|
|
(1) S&P / Moody's
(2) Sales in territories for which Royalty Pharma receives royalties.
(3) Aggregate end-user sales of all products; Royalty Pharma receives royalties on emtricitabine-related portion.
(4) Approved in select EU countries and Japan.
|
|
